- Home
- ETO vs CLLS Comparison
ETO vs CLLS Comparison
Compare ETO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ETO | CLLS |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.2M | 384.3M |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ETO | CLLS |
|---|---|---|
| Price | $27.09 | $3.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 42.1K | ★ 45.6K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.05 | $1.17 |
| 52 Week High | $31.11 | $5.48 |
Technical Indicators
Market Signals| Indicator | ETO | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | 47.16 |
| Support Level | $26.02 | $3.32 |
| Resistance Level | $27.67 | $3.83 |
| Average True Range (ATR) | 0.59 | 0.19 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 53.46 | 59.70 |
Price Performance
Historical ComparisonAbout ETO Eaton Vance Tax-Advantage Global Dividend Opp
Eaton Vance Tax-advtgd Global Divid Oppo is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. The portfolio of investments consists of capital markets, chemicals, diversified, beverages, banks, electric utilities, oil, gas and consumable fuels, personal products, and other areas.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.